Current evidence based on randomized controlled trial data has resulted in the Food and Drug Administration (FDA) approval for intravenous (IV) recombinant tissue plasminogen activator (rt-PA) within three hours from stroke symptom onset while mechanical embolectomy now has evidentiary support for zero to six hour cases and a specific subset of patient’s out to 24 hours [6-8]. Although IV rt-PA is approved for all arterial stroke distributions, mechanical embolectomy is only strongly supported for anterior circulation large vessel occlusions [8]. Here, PLAT is linked to stroke disorder.